nanotech-investing Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 05 February
nanotech-investing Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones 08 January
nanotech-investing Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting 03 November 2025
